Ganetespib radiosensitization for liver cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Radiotherapy

Background:

• Liver cancer therapies, especially radiation, remain insufficient.
• Inhibiting stress response pathways, like heat-shock-protein-90 (HSP90), is a potential anti-cancer strategy.
• HSP90 is overexpressed in liver cancer and supports cancer cell survival and radioresistance.

Purpose of the Study:

• To evaluate the efficacy of ganetespib, a novel HSP90 inhibitor, in combination with radiation therapy for liver cancer.
• To investigate the molecular mechanisms underlying the combined treatment's effects on liver cancer cells.
• To assess the in vivo anti-tumor activity of ganetespib and radiation combination therapy.

Main Methods:

• In vitro assays were performed on Hep3b, HepG2, and HUH7 liver cancer cell lines to assess clonogenic survival, apoptosis, cell cycle distribution, and DNA damage (γH2AX foci).
• Client protein expression in key signaling pathways (PI3K/AKT/mTOR, RAS/MAPK) was analyzed.
• In vivo studies involved evaluating tumor growth delay and proliferation in a HepG2 hind-flank tumor graft model.

Main Results:

• Ganetespib alone demonstrated anti-cancer activity in vitro, reducing cell survival and inducing apoptosis and G2-M cell cycle arrest.
• The combination of ganetespib and radiation resulted in supra-additive radiosensitization across all tested liver cancer cell lines, with enhancement ratios from 1.33 to 1.78.
• In vivo, the ganetespib-radiation combination therapy significantly inhibited tumor growth compared to monotherapy in HepG2 tumor grafts.

Conclusions:

• Combined ganetespib-radiation therapy shows significant supra-additive anti-cancer activity against liver cancer cells in vitro and in vivo.
• Ganetespib effectively sensitizes liver cancer cells to radiation by modulating key survival pathways.
• This combination therapy represents a promising strategy for liver cancer treatment, warranting further clinical investigation.